Park, Changhee Jeong, Kyeonghun Park, Joon-Hyeong Jung, Sohee Bae, Jeong Mo Kim, Kwangsoo Ock, Chan-Young Kim, Miso Keam, Bhumsuk Kim, Tae Min
...
Published in
Cancer immunology, immunotherapy : CII
Tumor immunogenicity is driven by various genomic and transcriptomic factors but the association with the overall status of methylation aberrancy is not well established. We analyzed The Cancer Genome Atlas pan-cancer database to investigate whether the overall methylation aberrancy links to the immune evasion of tumor. We created the definitions o...
Peiffer, Lukas Farahpour, Farnoush Sriram, Ashwin Spassova, Ivelina Hoffmann, Daniel Kubat, Linda Stoitzner, Patrizia Gambichler, Thilo Sucker, Antje Ugurel, Selma
...
Published in
Cancer immunology, immunotherapy : CII
Combined inhibition of BRAF/MEK is an established therapy for melanoma. In addition to its canonical mode of action, effects of BRAF/MEK inhibitors on antitumor immune responses are emerging. Thus, we investigated the effect of these on adaptive immune responses. Sequential tumor biopsies obtained before and during BRAF/MEK inhibitor treatment of f...
Takheaw, Nuchjira Sittithumcharee, Gunya Kariya, Ryusho Kasinrerk, Watchara Okada, Seiji
Published in
Cancer immunology, immunotherapy : CII
CD99 is a surface molecule expressed on various cell types including cancer cells. Expression of CD99 on multiple myeloma is associated with CCND1-IGH fusion/t(11;14). This translocation has been reported to be a genetic hallmark of mantle cell lymphoma (MCL). MCL is characterized by overexpression of cyclin D1 and high tumor proliferation. In this...
Takamori, Shinkichi Takada, Kazuki Shimokawa, Mototsugu Jinnnouchi, Mikako Matsubara, Taichi Haratake, Naoki Miura, Naoko Toyozawa, Ryo Yamaguchi, Masafumi Takenoyama, Mitsuhiro
...
Published in
Cancer immunology, immunotherapy : CII
Immune checkpoint inhibitors (ICIs) have become a standard therapy in non-small cell lung cancer (NSCLC). Although lung cancer adjoining emphysematous bullae (Ca-ADJ) were reported to express higher programmed cell death-ligand 1 (PD-L1), the predictive impact of Ca-ADJ on the response to ICIs is unknown. Two hundred and fifty-seven advanced or rec...
Liu, Qingzhu Jiang, Lei Li, Ke Li, Hang Lv, Gaochao Lin, Jianguo Qiu, Ling
Published in
Cancer immunology, immunotherapy : CII
The checkpoint blockade immunotherapy has become a potent treatment strategy for cancers, and programmed death ligand-1 (PD-L1) is a prominent checkpoint ligand that is highly expressed in some cancers. The identification of immune checkpoint marker PD-L1 is critical for improving the success of immunotherapy. Accordingly, the binding specificity a...
de Jong, G Bartels, L Kedde, M Verdegaal, E M E Gillissen, M A Levie, S E Cercel, M G van Hal-van Veen, S E Fatmawati, C van de Berg, D
...
Published in
Cancer immunology, immunotherapy : CII
Targeted cancer therapy with monoclonal antibodies has proven successful for different cancer types but is limited by the availability of suitable antibody targets. CD43s, a unique sialylated form of CD43 expressed by hematologic malignancies, is a recently identified target and antibodies interacting with CD43s may have therapeutic potential again...
Zhao, Zhe Wang, Xinfeng Bao, Xiu-Qi Ning, Jingwen Shang, Meiyu Zhang, Dan
Published in
Cancer immunology, immunotherapy : CII
To summarize the clinical characteristics and immunological and genetic features of patients who developed autoimmune polyendocrine syndrome type II (APS-2) after treatment with immune checkpoint inhibitors (ICIs). Several databases (MEDLINE/EMBASE/Cochrane) were searched for studies published between January 2000 and February 2020 involving patien...
Zamora, Carlos Riudavets, Mariona Anguera, Georgia Alserawan, Letícia Sullivan, Ivana Barba, Andrés Serra, Jorgina Ortiz, M Angels Gallardo, Pablo Perea, Lidia
...
Published in
Cancer immunology, immunotherapy : CII
Anti-PD-(L)1 blocking agents can induce immune-related adverse events (irAEs), which can compromise treatment continuation. Since circulating leukocyte-platelet (PLT) complexes contribute to inflammatory and autoimmune diseases, we aimed to analyze the role of these complexes as predictors of irAEs in non-small cell lung cancer (NSCLC) patients rec...
Di Noia, Vincenzo D'Argento, Ettore Pilotto, Sara Vita, Emanuele Ferrara, Miriam Grazia Damiano, Paola Ribelli, Marta Cannella, Antonella Virtuoso, Antonella Fattorossi, Andrea
...
Published in
Cancer immunology, immunotherapy : CII
Identifying the patients who may benefit the most from immune checkpoints inhibitors remains a great challenge for clinicians. Here we investigate on blood serum amyloid A (SAA) as biomarker of response to upfront pembrolizumab in patients with advanced non-small-cell lung cancer (NSCLC). Patients with PD-L1 ≥ 50% receiving upfront pembrolizumab (P...
Dymicka-Piekarska, Violetta Koper-Lenkiewicz, Olga M Zińczuk, Justyna Kratz, Ewa Kamińska, Joanna
Published in
Cancer immunology, immunotherapy : CII
It is well known that various inflammatory cells infiltrate cancer cells. Next to TAMs (tumor-associated macrophages), TAFs (tumor-associated fibroblasts) and TANs (tumor-associated neutrophils) also platelets form the tumor microenvironment. Taking into account the role of platelets in the development of cancer, we have decided to introduce a new ...
